Cargando…

MDR1-EXPRESSING CD4(+) T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE

BACKGROUND: Multidrug resistance-1 (MDR1) transporter limits the intracellular accumulation of chemotherapies (paclitaxel, anthracyclines) used in breast cancer (BC) treatment. In addition to tumor cells, MDR1 is expressed on immune cell subsets in which it confers chemoresistance. Among human T cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Roio, Anthony, Hubert, Margaux, Besson, Laurie, Bossennec, Marion, Rodriguez, Céline, Grinberg-Bleyer, Yenkel, Lalle, Guilhem, Moudombi, Lyvia, Schneider, Raphael, Degletagne, Cyril, Treilleux, Isabelle, Campbell, Daniel J, Metzger, Séverine, Duhen, Thomas, Trédan, Olivier, Caux, Christophe, Ménétrier-Caux, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632904/ https://www.ncbi.nlm.nih.gov/pubmed/37940345 http://dx.doi.org/10.1136/jitc-2023-007733

Ejemplares similares

MDR1 in immunity: friend or foe?
por: Bossennec, Marion, et al.
Publicado: (2018)

Methotrexate Restores CD73 Expression on Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis Patients and May Contribute to Its Anti-Inflammatory Effect through Ado Production
por: Bossennec, Marion, et al.
Publicado: (2019)

NF-κB in Cancer Immunity: Friend or Foe?
por: Lalle, Guilhem, et al.
Publicado: (2021)

Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?
por: Cinier, Justine, et al.
Publicado: (2021)

CD73 expression and clinical significance in human metastatic melanoma
por: Monteiro, Inês, et al.
Publicado: (2018)

CD163(+) tumor‐associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes
por: Ramos, Rodrigo Nalio, et al.
Publicado: (2020)

Gene signature of circulating platelet‐bound neutrophils is associated with poor prognosis in cancer patients
por: Lecot, Pacôme, et al.
Publicado: (2022)

Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
por: Ménétrier-Caux, Christine, et al.
Publicado: (2019)

Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
por: Cassier, Philippe A, et al.
Publicado: (2011)

Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment
por: Ménétrier-Caux, Christine, et al.
Publicado: (2012)

ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4(+) T cells by plasmacytoid dendritic cells
por: Faget, Julien, et al.
Publicado: (2013)

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
por: Vigano, Selena, et al.
Publicado: (2019)

Transcriptional Control of Regulatory T Cells in Cancer: Toward Therapeutic Targeting?
por: Stéphan, Pierre, et al.
Publicado: (2020)

Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study
por: Mery, Benoîte, et al.
Publicado: (2023)

Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3(+) regulatory T cells and are associated with poor prognosis in breast cancer patients
por: Sisirak, Vanja, et al.
Publicado: (2013)

Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay
por: Verronèse, E., et al.
Publicado: (2015)

A T cell-intrinsic function for NF-κB RelB in experimental autoimmune encephalomyelitis
por: Lalle, Guilhem, et al.
Publicado: (2021)

A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system
por: Burlion, Aude, et al.
Publicado: (2019)

Disequilibrium of BMP2 Levels in the Breast Stem Cell Niche Launches Epithelial Transformation by Overamplifying BMPR1B Cell Response
por: Chapellier, Marion, et al.
Publicado: (2015)

Renal cell carcinoma induces interleukin 10 and prostaglandin E(2) production by monocytes
por: Ménétrier-Caux, C, et al.
Publicado: (1999)

Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome
por: Bachelot, T, et al.
Publicado: (2006)

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
por: Bachelot, T, et al.
Publicado: (2003)

Effect of acute aerobic exercise before immunotherapy and chemotherapy infusion in patients with metastatic non-small-cell lung cancer: protocol for the ERICA feasibility trial
por: Gouez, Manon, et al.
Publicado: (2022)

ZEB1 transcription factor promotes immune escape in melanoma
por: Plaschka, Maud, et al.
Publicado: (2022)

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients
por: Manuel, Manuarii, et al.
Publicado: (2012)

Human Tumor-Infiltrating Dendritic Cells: From In Situ Visualization to High-Dimensional Analyses
por: Hubert, Margaux, et al.
Publicado: (2019)

An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020)

IMMU-03. UPDATES ON BRAINCHILD-01, -02, AND -03: PHASE 1 LOCOREGIONAL CAR T CELL TRIALS TARGETING HER2, EGFR, AND B7-H3 FOR CHILDREN WITH RECURRENT CNS TUMORS AND DIPG
por: Vitanza, Nicholas, et al.
Publicado: (2020)

IMMU-10. INTERIM ANALYSIS OF THE HIT-HGG REZ IMMUNVAC STUDY - DENDRITIC CELL VACCINATION WITH PARTIAL TREG DEPLETION IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RELAPSED HIGH-GRADE GLIOMAS
por: Eyrich, Matthias, et al.
Publicado: (2020)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)

IMMU-23. A NOVEL MASS CYTOMETRY-BASED MULTI-PARAMETER CHARACTERIZATION OF NEOANTIGEN-REACTIVE CD8+ T-CELLS IN PATIENTS PARTICIPATING IN PNOC007 H3.3K27M PEPTIDE VACCINE CLINICAL TRIAL
por: Taitt, Jared, et al.
Publicado: (2020)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

IMMU-29. AIF1 IS A PROGNOSTIC BIOMARKER AND CORRELATED WITH IMMUNE INFILTRATES IN GLIOMAS
por: Chai, Yi, et al.
Publicado: (2020)

IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH
por: Houke, Haley, et al.
Publicado: (2020)

IMMU-02. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL NEUROTOXICITY CORRELATES WITH PRETREATMENT AND ACUTE CSF NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS
por: Gust, Juliane, et al.
Publicado: (2020)

IMMU-21. INVESTIGATION OF WHITE BLOOD CELL CHARACTERISTICS IN CSF SAMPLES AT PEDIATRIC BRAIN TUMOR DIAGNOSIS
por: Greer, Hunter, et al.
Publicado: (2020)

IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020)

IMMU-13. DUAL IGF1R/IR INHIBITOR IN COMBINATION WITH GD2-CAR T-CELLS AS A POTENT THERAPEUTIC STRATEGY FOR H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS
por: de Billy, Emmanuel, et al.
Publicado: (2020)

IMMU-31. PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)
por: Mueller, Sabine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jg1ugr0fglmdc3fahnnq0i7jhq